U.S. Food and Drug Administration Approves Opdivo? (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma

- OpdivoPrescribing Information.?OpdivoU.S. Product Information. Last updated: August 2021. Princeton, NJ: Bristol-Myers Squibb Company.
- U.S. Food & Drug Administration. Real-Time Oncology Review Pilot Program.?https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review-pilot-program. Accessed August 03, 2021.
- Salama A, Abdelmaksound M, Shawki A, et al. Outcome of Muscle-Invasive Urothelial Bladder Cancer After Radical Cystectomy.?Clinical Genitourinary Cancer.2016;14(1):43-47.
- American Cancer Society. About Bladder Cancer.?https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html. Accessed August 03, 2021.
- SEER. Cancer Stat Facts: Bladder Cancer.?
Share this article on WhatsApp, LinkedIn and Twitter
X


Incisive News in 3 Shots.
Contact Us
- First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
- +91-120 428 0707
- connect@pharmashots.com
- Newsletter
Our Information
Copyright © 2025 PharmaShots - All Rights Reserved.
Modal title
Modal body text goes here.